-
Over the past 30 years, allogeneic hematopoietic stem cell transplantation outcomes in patients with acute lymphoblastic leukemia have generally improved, but transplant outcomes in this type of patient need to be improved
Time of Update: 2022-10-13
Figure 2 RR and NRM in patients undergoing allo-HSCT in different disease states and at different timesIn addition, in patients transplanted during CR1, the improvement in RR in Ph+ patients over time was more pronounced than in non-Ph patients, with a 5-year corrected RR of 39.
-
Summary: An exploration of immunotherapy strategies for stage III non-small cell lung cancer
Time of Update: 2022-10-13
Figure 1 Calculation of PFS for different treatment strategies is differentTable1 Randomized controlled studies with completed or preliminary data in unresectable stage III NSCLC (from the references, not the latest data) Table 2 Ongoing Phase II/III studies in unresectable stage III NSCLCConsolidation immunotherapy after synchronous or sequential CRT The immunomonotherapy monotherapy single-arm Phase II LUN14-179 trial (n=93) evaluated the results of 1-year treatment with pabolizumab in patients with unresectable NSCLC sequentially, and the study reached the primary endpoints: 30.
-
Express Improved antibody-coupled drugs target a variety of solid tumors, and the new sharp completed a $68 million Series A financing
Time of Update: 2022-10-13
▲Pheon R&D pipeline (Source: Pheon official website)Pheon's main project, PHN-010, targets a target that is highly expressed in many solid tumors (target names have not yet been revealed) and is expected to file for a new drug clinical trial (IND) application over the next 18 months.
-
CA Heavyweight Clinical Management Strategy for Precise Treatment of Metastatic Colorectal Cancer in the Era
Time of Update: 2022-10-13
The data show that the KRAS G12C mutation occurs in about 3%-4% of mCRCs, and a number of studies are currently evaluating the efficacy of these two drugs combined with anti-EGFR monoclonal antibodies for second- and third-line treatment in mCRC patients.
-
Express In the treatment of non-small cell lung cancer, GSK has made excellent clinical progress in the development of PD-1 antibodies and TIM-3 inhibitors
Time of Update: 2022-10-13
According to the press release, Jemperli reached the primary endpoint of the trial in the largest head-to-head PD-1 inhibitor trial to date in the metastatic non-small cell lung cancer (NSCLC) patient population.
-
Half of the world's esophageal cancer is in China, and listen to Professor Fu Junhui explain the key points of esophageal cancer treatment!
Time of Update: 2022-10-13
"Series of research on surgical treatment of esophageal cancer" won the first prize of Shantou Science and Technology Achievement Award 3 times in 2009, 2014 and 2015 Shantou City outstanding talentsNan Yue good doctorDirector of Esophageal Surgery, National Center for Respiratory Medicine/First Affiliated Hospital of Guangzhou Medical UniversityDirector of the Department of Oncology of Shantou Central Hospital (Guangdong Provincial Clinical Key Specialty).
-
Write a new chapter in standardized diagnosis and treatment, create an infinite future of MM, and open the MM standardized diagnosis and treatment Sino-foreign exchange series of China-Europe station wonderfully
Time of Update: 2022-10-13
Multiple myeloma (MM) is a malignant disease with abnormal proliferation of clonal plasma cells with a high degree of heterogeneity, and the survival prognosis of patients is very different. Different
-
Professor Zhang Qingyuan: Pola's three major offensive tools (3) - crackable connectors, ADC drugs "strong and low toxicity" guarantee
Time of Update: 2022-10-13
GuideEvery opening of the unknown world has the brave foresight of pioneers; Every journey of sneaking in the dark night, there is a little lamp man fearlessly leading the way. The series of reports "
-
JCO: Pre-chemotherapy inflammatory markers are associated with worsening of clinical symptoms caused by chemotherapy in elderly breast cancer patients
Time of Update: 2022-10-13
The results of a study from J Clin Oncol suggest that pre-chemotherapy high interleukin-6 (IL-6) and C-reactive protein (CRP) are associated with a decrease in debilitating states due to chemotherapy, independent of sociodemographic and clinical risk factors.
-
This most common breast cancer, 1/4 of patients in a timely change of treatment strategy benefits significantly!
Time of Update: 2022-10-13
Overall, the results of the current study suggest that it is necessary for patients with ER+/HER2-advanced breast cancer to monitor the occurrence of relevant resistance mutations (such as blood ESR1 mutations) in the blood during standard first-line therapy (aromatase inhibitors + CDK4/6 inhibitors).
-
Professor Sun Beicheng et al.'s latest "Nature": collagen lysis-dependent DDR1 signaling determines the prognosis of pancreatic cancer
Time of Update: 2022-10-13
▎Editor of WuXi AppTec content team Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a short average survival of five years and no effective treatment 。 This week, Professor Su
-
Bronchial tumors, multi-organ invasions! But not malignant, not benign...
Time of Update: 2022-10-13
Malignant?Epstein-Barr virus-associated leiomyomas (EBV SMTs) are rare mesenchymal tumors found only in immunocompromised hosts and are divided into three separate clinicopathological subtypes depending on the cause of immunodeficiency: HIV-related, post-transplant, and congenital immunodeficiency-associated leiomyomas.
-
2022CSH Prof. Kailin Xu: The powerful combination of CAR-T and allo-HSCT benefits patients with B-ALL even more
Time of Update: 2022-10-13
Application of CAR-T cell therapy in combination with HSCT in R/R B-ALLCAR-T sequentially allo-HSCTIn order to improve the long-term efficacy of CAR-T cell therapy, Chinese researchers have explored the role of bridging allo-HSCT in B-ALL after CAR-T cell therapy 。 Beijing Lu Daopei Hospital conducted a clinical trial of 135 patients who obtained CR after CAR-T cell therapy, and bridging allo-HSCT after reaching CR, and the results showed that the 2-year OS rate of MRD-negative CR patients could reach 83.
-
【Nature Subjournal】Tang Fuyi/Wang Jie's team revealed tumor heterogeneity of small cell lung cancer through single-cell transcriptomic spectrometry
Time of Update: 2022-10-13
However, while single-cell transcriptomic analysis has been performed on most cancer types, there are still no scRNA-seq studies on matched primary tumors (PTs), normal lung tissue near tumors (NAT), and recurrent tumors (RTs).
-
2022CSH Professor Zhang Huilai: "No chemotherapy" improves the quality of life of patients with indolent lymphoma, and precise stratification brings the dawn of cure for R/R patients
Time of Update: 2022-10-13
The 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25, 2022, with the theme of "respect, inheritance, collaboration and
-
【PNAS】Wu Jianmin/Ji Jiafu team of Peking University Cancer Hospital discovered a new mechanism of metabolic reprogramming of gastric cancer cells
Time of Update: 2022-10-13
This article is the original of the translational medicine network, please indicate the source when reprinting Author: SophiaIntroduction: Gastric cancer refers to a malignant tumor of the upper gastr
-
Sci Rep: Worthy of being an "angel in cancer"?
Time of Update: 2022-10-12
86), and a history of thyroid cancer may be a protective factor for liver cancer death in PLC patients (Table 3) .
86), and a history of thyroid cancer may be a protective factor for liver cancer death in PLC patients (Table 3) .
-
"Cell": Scientists reveal immune profiles of different tumor types
Time of Update: 2022-10-12
In a study titled "Discovering dominant tumor immune archetypes in a pan-cancer census" published in Cell, UCSF and multiple research teams identified and classified immune archetypes in 12 different tumor types.
-
Deepening the Impression - A Case of Inflammatory Myofibroblastic Tumor of Esophagus and Gastric
Time of Update: 2022-10-12
CT examination showed that the esophageal wall in the lower esophagus and the gastric wall in the cardia area were significantly thickened unevenly, and the esophageal cavity was narrowed; a mass of high-density shadow was seen at the fundus of the stomach, no tumor grew significantly outside the wall, and no obvious surrounding lymph nodes were found ( Figure C) .
-
Nature sub-journal: Earlier detection of lung cancer at the cellular level!
Time of Update: 2022-10-12
RELATED: Researchers at the Abramson Cancer Center at the University of Pennsylvania have found a way to identify lung cancers at the cellular level in real time during biopsies, offering hope for earlier, more confident disease detection .
